NO327426B1 - Torrpulverpreparat, fremgangsmate for fremstilling samt anvendelse av nevnte preparat - Google Patents
Torrpulverpreparat, fremgangsmate for fremstilling samt anvendelse av nevnte preparat Download PDFInfo
- Publication number
- NO327426B1 NO327426B1 NO19993539A NO993539A NO327426B1 NO 327426 B1 NO327426 B1 NO 327426B1 NO 19993539 A NO19993539 A NO 19993539A NO 993539 A NO993539 A NO 993539A NO 327426 B1 NO327426 B1 NO 327426B1
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- preparation according
- particles
- formoterol
- budesonide
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 27
- 239000000843 powder Substances 0.000 title claims description 21
- 238000000034 method Methods 0.000 title claims description 15
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 18
- 229960004436 budesonide Drugs 0.000 claims description 18
- 239000002245 particle Substances 0.000 claims description 18
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 9
- 229960002848 formoterol Drugs 0.000 claims description 9
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 9
- 229960001021 lactose monohydrate Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229960001375 lactose Drugs 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 238000005054 agglomeration Methods 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 4
- 230000003750 conditioning effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 2
- 238000005563 spheronization Methods 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229960004793 sucrose Drugs 0.000 claims description 2
- 229940074410 trehalose Drugs 0.000 claims description 2
- NWLPAIVRIWBEIT-SEPHDYHBSA-N (e)-but-2-enedioic acid;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O NWLPAIVRIWBEIT-SEPHDYHBSA-N 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 17
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 description 13
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 description 13
- 238000009472 formulation Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000007873 sieving Methods 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 230000001143 conditioned effect Effects 0.000 description 4
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 229960005105 terbutaline sulfate Drugs 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXNFKCQMGMBBJ-UHFFFAOYSA-N [1-(dimethylamino)-2-[(dimethylamino)methyl]butan-2-yl] benzoate Chemical compound CN(C)CC(CC)(CN(C)C)OC(=O)C1=CC=CC=C1 VEXNFKCQMGMBBJ-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9700135A SE9700135D0 (sv) | 1997-01-20 | 1997-01-20 | New formulation |
| PCT/SE1998/000040 WO1998031352A1 (en) | 1997-01-20 | 1998-01-13 | New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO993539D0 NO993539D0 (no) | 1999-07-19 |
| NO993539L NO993539L (no) | 1999-09-20 |
| NO327426B1 true NO327426B1 (no) | 2009-06-29 |
Family
ID=20405455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19993539A NO327426B1 (no) | 1997-01-20 | 1999-07-19 | Torrpulverpreparat, fremgangsmate for fremstilling samt anvendelse av nevnte preparat |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US6030604A (et) |
| EP (1) | EP1007017B2 (et) |
| JP (1) | JP2010059181A (et) |
| KR (1) | KR100528416B1 (et) |
| CN (1) | CN1271993C (et) |
| AR (1) | AR011080A1 (et) |
| AT (1) | ATE288260T1 (et) |
| AU (1) | AU731192B2 (et) |
| BR (1) | BR9811249A (et) |
| CA (1) | CA2277913C (et) |
| CZ (1) | CZ296301B6 (et) |
| DE (1) | DE69828886T3 (et) |
| DK (1) | DK1007017T4 (et) |
| EE (1) | EE03951B1 (et) |
| ES (1) | ES2235311T5 (et) |
| HK (1) | HK1025515A1 (et) |
| HU (1) | HU228622B1 (et) |
| ID (1) | ID21865A (et) |
| IL (1) | IL130838A (et) |
| IS (1) | IS2788B (et) |
| MY (1) | MY132999A (et) |
| NO (1) | NO327426B1 (et) |
| NZ (1) | NZ336594A (et) |
| PL (1) | PL192115B1 (et) |
| PT (1) | PT1007017E (et) |
| RU (1) | RU2194497C2 (et) |
| SA (1) | SA98180818B1 (et) |
| SE (1) | SE9700135D0 (et) |
| SI (1) | SI1007017T2 (et) |
| SK (1) | SK283950B6 (et) |
| TR (1) | TR199901690T2 (et) |
| TW (1) | TW557217B (et) |
| UA (1) | UA57764C2 (et) |
| WO (1) | WO1998031352A1 (et) |
| ZA (1) | ZA9878B (et) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| US6503537B2 (en) | 1997-03-20 | 2003-01-07 | Schering Corporation | Preparation of powder agglomerates |
| US6495167B2 (en) | 1997-03-20 | 2002-12-17 | Schering Corporation | Preparation of powder agglomerates |
| SE9703407D0 (sv) * | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| SE9802073D0 (sv) * | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| GB9826284D0 (en) * | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
| GB9826286D0 (en) * | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
| ES2207867T3 (es) * | 1998-12-11 | 2004-06-01 | Pharmachemie B.V. | Preparacion farmaceutica para inhalacion de un opioide. |
| US8722668B2 (en) * | 1998-12-23 | 2014-05-13 | Daryl W. Hochman | Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders |
| AR022695A1 (es) * | 1999-01-28 | 2002-09-04 | Schering Corp | PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION |
| US6623760B1 (en) * | 1999-01-28 | 2003-09-23 | Schering Corporation | Method of preparing particles for agglomeration |
| GB9903759D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| GB9904919D0 (en) * | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
| EP1169053A1 (en) * | 1999-04-13 | 2002-01-09 | Inhale Therapeutic Systems, Inc. | Pulmonary administration of dry powder formulations for treating infertility |
| CA2273585A1 (en) | 1999-05-28 | 2000-11-28 | Canpolar East Inc. | Sensors for detecting changes in temperature, ph, chemical conditions, biological conditions, radiation, electrical field and pressure |
| DE19962926A1 (de) * | 1999-12-24 | 2001-06-28 | Bayer Ag | Verfahren zur Co-Mahlung von Stoffen und Lactose mittels Strahlmühlen |
| US6369115B1 (en) * | 2000-03-20 | 2002-04-09 | Dura Pharmaceuticals, Inc. | Stabilized powder formulations |
| WO2001078735A1 (en) * | 2000-04-13 | 2001-10-25 | Innovata Biomed Limited | Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
| GB0012260D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
| GB0012261D0 (en) * | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
| CA2417973A1 (en) * | 2000-08-04 | 2002-02-14 | Longwood Pharmaceutical Research, Inc. | Formulations of mometasone and a bronchodilator for pulmonary administration |
| FI20002177A0 (fi) * | 2000-10-02 | 2000-10-02 | Orion Yhtymae Oyj | Uusi yhdistelmä astman hoitoon |
| FI20002215A0 (fi) * | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
| FI20002216A0 (fi) * | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit astman hoitoon |
| BR0207062A (pt) * | 2001-02-06 | 2004-10-05 | Innovata Biomed Ltd | Composição farmacêutica bimodal, inalador para pó seco, método de aplicação de uma quantidade terapeuticamente eficaz de um ingrediente ativo substancialmente fino aos pulmões de um paciente, método de tratamento de um distúrbio respiratório, método de tratamento de doença pulmonar obstrutiva crÈnica (copd), uso de um agente antiinflamatório, uso de um broncodilatador, uso de uma mistura de um agente antiinflamatório e de um broncodilatador, e, processo para a fabricação de uma composição farmacêutica bimodal |
| US20030055026A1 (en) * | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| TWI324934B (en) * | 2001-08-28 | 2010-05-21 | Schering Corp | Pharmaceutical compositions for the treatment of asthma |
| US7931022B2 (en) * | 2001-10-19 | 2011-04-26 | Respirks, Inc. | Method and apparatus for dispensing inhalator medicament |
| US20030140920A1 (en) * | 2001-10-26 | 2003-07-31 | Dey L.P. | Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma |
| US20030191151A1 (en) * | 2001-10-26 | 2003-10-09 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
| JP2003221335A (ja) | 2001-10-26 | 2003-08-05 | Dey Lp | 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法 |
| US6702997B2 (en) | 2001-10-26 | 2004-03-09 | Dey, L.P. | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
| US20030203930A1 (en) * | 2001-10-26 | 2003-10-30 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
| GB0208609D0 (en) * | 2002-04-13 | 2002-05-22 | Glaxo Group Ltd | Compositions |
| RS95304A (en) * | 2002-05-07 | 2006-12-15 | Altana Pharma Ag. | New combination fortreating airway disorders |
| US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
| GB0219511D0 (en) * | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Method of preparing dry powder inhalation compositions |
| GB0219512D0 (en) * | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Inhalation compositions with high drug ratios |
| KR101369631B1 (ko) * | 2002-08-21 | 2014-03-05 | 노턴 헬스케어 리미티드 | 흡입용 조성물 |
| US20050158248A1 (en) * | 2002-08-21 | 2005-07-21 | Xian-Ming Zeng | Method of preparing dry powder inhalation compositions |
| CN1694689A (zh) * | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | 供吸入的缓释多孔微粒 |
| US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
| DK1572217T3 (da) * | 2002-12-12 | 2008-12-15 | Nycomed Gmbh | Kombinationsmedikament af R,R-formoterol og ciclesonid |
| US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
| US6962006B2 (en) * | 2002-12-19 | 2005-11-08 | Acusphere, Inc. | Methods and apparatus for making particles using spray dryer and in-line jet mill |
| EP1452179A1 (en) * | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| US20040191176A1 (en) * | 2003-03-28 | 2004-09-30 | Kaplan Leonard W | Formulations for treatment of pulmonary disorders |
| WO2004103379A1 (en) * | 2003-05-22 | 2004-12-02 | Altana Pharma Ag | Salmeterol and ciclesonide combination |
| SE526850C2 (sv) * | 2003-06-19 | 2005-11-08 | Microdrug Ag | Farmaceutisk kombinerad torr pulverdos separerade på gemensam dosbädd |
| SE527190C2 (sv) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid |
| SE526509C2 (sv) * | 2003-06-19 | 2005-09-27 | Microdrug Ag | Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd |
| SE527189C2 (sv) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel |
| SE527200C2 (sv) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av formaterol och fluticason |
| TWI359675B (en) * | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| GB0316335D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Pharmaceutical formulations |
| ATE498394T1 (de) | 2003-09-02 | 2011-03-15 | Norton Healthcare Ltd | Verfahren zur herstellung eines medikaments |
| ES2452691T5 (es) * | 2003-09-16 | 2022-09-14 | Covis Pharma Gmbh | Uso de ciclesonida para el tratamiento de enfermedades respiratorias |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US20070020298A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
| ES2293530T3 (es) * | 2004-01-22 | 2008-03-16 | Pfizer, Inc. | Derivados de sulfonamidas para el tratamiento de enfermedades. |
| JO3102B1 (ar) * | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة |
| AR048339A1 (es) * | 2004-03-24 | 2006-04-19 | Chiesi Farma Spa | Monoclorhidrato de 8- hidroxi-5-((1r)) -1- hidroxi-2- (((1r)-2 ( 4-metoxifenil) -1- metiletil) amino ) eti l) -2 (1h) - quinolinona en form acristalina y el proceso para su preparacion |
| JP2007533706A (ja) * | 2004-04-20 | 2007-11-22 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 喫煙患者における呼吸器疾患の治療のためのシクレソニドの使用 |
| CA2562386C (en) | 2004-04-21 | 2014-11-18 | Innovata Biomed Limited | Inhaler |
| GB0409197D0 (en) | 2004-04-24 | 2004-05-26 | Innovata Biomed Ltd | Device |
| EP2311793A1 (en) * | 2004-12-17 | 2011-04-20 | Cipla Ltd. | Crystalline levosalbutamol sulphate (Form II) |
| CN104177448A (zh) * | 2005-02-10 | 2014-12-03 | 葛兰素集团有限公司 | 使用预分选技术制备乳糖的方法以及由此形成的药物制剂 |
| WO2007011743A2 (en) | 2005-07-14 | 2007-01-25 | Lipothera, Inc. | Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
| US8475845B2 (en) * | 2005-07-15 | 2013-07-02 | Map Pharmaceuticals, Inc. | Method of particle formation |
| AU2006269961B2 (en) * | 2005-07-15 | 2012-07-19 | Map Pharmaceuticals, Inc. | Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof |
| EP1973523A2 (en) * | 2005-12-15 | 2008-10-01 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
| JP2009519970A (ja) * | 2005-12-15 | 2009-05-21 | アキュスフィア， インコーポレイテッド | 粒子ベースの経口投与用製薬剤形の製造方法 |
| US7913223B2 (en) * | 2005-12-16 | 2011-03-22 | Dialogic Corporation | Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system |
| JP2010506941A (ja) * | 2006-10-17 | 2010-03-04 | リセラ，インク． | 甲状腺眼症の治療のための方法、組成物及び製剤 |
| WO2008100727A2 (en) | 2007-02-14 | 2008-08-21 | The Trustees Of Columbia University In The City Of New York | High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders |
| ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
| GB0714134D0 (en) * | 2007-07-19 | 2007-08-29 | Norton Healthcare Ltd | Dry-powder medicament |
| DE102007049931A1 (de) | 2007-10-18 | 2009-04-23 | Pharmatech Gmbh | Vorrichtung und Verfahren zur kontinuierlichen Herstellung von sphärischen Pulveragglomeraten |
| US20100120737A1 (en) * | 2008-11-10 | 2010-05-13 | Martin Feth | Amorphous ciclesonide |
| US20100291221A1 (en) * | 2009-05-15 | 2010-11-18 | Robert Owen Cook | Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation |
| US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| AU2010253776B2 (en) | 2009-05-29 | 2015-01-22 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems |
| SG182485A1 (en) * | 2010-01-15 | 2012-08-30 | Lithera Inc | Lyophilized cake formulations |
| US20110224229A1 (en) | 2010-03-10 | 2011-09-15 | Astrazeneca Ab | Novel Crystalline Form |
| MX2013004137A (es) | 2010-10-12 | 2013-07-29 | Cipla Ltd | Composicion farmaceutica. |
| CN103269693A (zh) | 2010-11-24 | 2013-08-28 | 利赛拉公司 | 选择性、亲脂性及长效型β激动剂单一治疗调配物和用于肥胖及外形凸起的美容治疗的方法 |
| US9402854B2 (en) | 2012-04-11 | 2016-08-02 | Cipla Limited | Pharmaceutical composition |
| RU2510267C2 (ru) * | 2012-06-15 | 2014-03-27 | Шолекс Девелопмент Гмбх | Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения |
| WO2014144894A1 (en) | 2013-03-15 | 2014-09-18 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
| TR201802969T4 (tr) | 2013-07-01 | 2018-03-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Yeni inhalasyon formülasyonları. |
| WO2019036483A1 (en) | 2017-08-15 | 2019-02-21 | Nephron Pharmaceuticals Corporation | AQUEOUS NEBULIZATION COMPOSITION |
| WO2020240350A1 (en) * | 2019-05-24 | 2020-12-03 | Glenmark Pharmaceutical Limited | An inhalable fixed dose powder composition comprising glycopyrronium, formoterol and fluticasone propionate |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1429184A (en) * | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US4161516A (en) † | 1975-07-25 | 1979-07-17 | Fisons Limited | Composition for treating airway disease |
| GB1571629A (en) * | 1977-11-30 | 1980-07-16 | Fisons Ltd | Pharmaceutical compositions containing beclomethasone dipropionate |
| CY1492A (en) * | 1981-07-08 | 1990-02-16 | Draco Ab | Powder inhalator |
| SE438261B (sv) * | 1981-07-08 | 1985-04-15 | Draco Ab | Anvendning i dosinhalator av ett perforerat membran |
| EP0072046B1 (en) * | 1981-07-24 | 1986-01-15 | FISONS plc | Inhalation drugs, methods for their production and pharmaceutical formulations containing them |
| GB8825541D0 (en) † | 1988-11-01 | 1988-12-07 | Fisons Plc | Formulation |
| ES2087911T3 (es) * | 1989-04-28 | 1996-08-01 | Riker Laboratories Inc | Dispositivo de inhalacion de polvo seco. |
| US5176132A (en) * | 1989-05-31 | 1993-01-05 | Fisons Plc | Medicament inhalation device and formulation |
| DE59100388D1 (de) † | 1990-01-29 | 1993-10-28 | Ciba Geigy | Verfahren und Vorrichtung zur Dosierung eines feinkörnigen Pulvers. |
| US5192548A (en) * | 1990-04-30 | 1993-03-09 | Riker Laboratoires, Inc. | Device |
| SE9100342D0 (sv) * | 1991-02-04 | 1991-02-04 | Astra Ab | Novel steroid esters |
| SE9100341D0 (sv) * | 1991-02-04 | 1991-02-04 | Astra Ab | Novel steroids |
| SE9101090D0 (sv) * | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
| SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| NZ243061A (en) * | 1991-06-10 | 1993-09-27 | Schering Corp | Aerosol containing a medicament and 1,1,1,2,3,3,3-heptafluoropropane |
| US5736124A (en) * | 1991-12-12 | 1998-04-07 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicament |
| WO1993011773A1 (en) * | 1991-12-18 | 1993-06-24 | Aktiebolaget Astra | New combination of formoterol and budesonide |
| US5355872B1 (en) * | 1992-03-04 | 1998-10-20 | John H Riggs | Low flow rate nebulizer apparatus and method of nebulization |
| ES2177544T3 (es) † | 1992-06-12 | 2002-12-16 | Teijin Ltd | Polvo ultrafinno para inhalar y metodo para su preparacion. |
| US5700410A (en) * | 1992-10-16 | 1997-12-23 | Nippon Shinyaku Co., Ltd. | Method of manufacturing wax matrices |
| BR9407287A (pt) * | 1993-08-18 | 1996-10-01 | Unilever Nv | Composição para barbear |
| IS1736B (is) * | 1993-10-01 | 1999-12-30 | Astra Ab | Aðferð og tæki sem stuðla að aukinni samloðun agna |
| DK0721331T3 (da) * | 1993-10-01 | 2002-02-11 | Astrazeneca Ab | Fremgangsmåde |
| GB9404945D0 (en) † | 1994-03-15 | 1994-04-27 | Glaxo Group Ltd | Pharmaceutical composition |
| US5647347A (en) * | 1994-10-21 | 1997-07-15 | Glaxo Wellcome Inc. | Medicament carrier for dry powder inhalator |
| US5503869A (en) * | 1994-10-21 | 1996-04-02 | Glaxo Wellcome Inc. | Process for forming medicament carrier for dry powder inhalator |
| US5654007A (en) * | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| SE9603669D0 (sv) * | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
-
1997
- 1997-01-20 SE SE9700135A patent/SE9700135D0/xx unknown
-
1998
- 1998-01-06 ZA ZA9878A patent/ZA9878B/xx unknown
- 1998-01-09 US US09/004,902 patent/US6030604A/en not_active Expired - Lifetime
- 1998-01-13 CA CA002277913A patent/CA2277913C/en not_active Expired - Lifetime
- 1998-01-13 CZ CZ0255799A patent/CZ296301B6/cs not_active IP Right Cessation
- 1998-01-13 NZ NZ336594A patent/NZ336594A/xx not_active IP Right Cessation
- 1998-01-13 AT AT98901618T patent/ATE288260T1/de active
- 1998-01-13 SI SI9830754T patent/SI1007017T2/sl unknown
- 1998-01-13 BR BR9811249-0A patent/BR9811249A/pt not_active Application Discontinuation
- 1998-01-13 EP EP98901618A patent/EP1007017B2/en not_active Expired - Lifetime
- 1998-01-13 AU AU57859/98A patent/AU731192B2/en not_active Expired
- 1998-01-13 WO PCT/SE1998/000040 patent/WO1998031352A1/en active IP Right Grant
- 1998-01-13 UA UA99074044A patent/UA57764C2/uk unknown
- 1998-01-13 DE DE69828886T patent/DE69828886T3/de not_active Expired - Lifetime
- 1998-01-13 HU HU0000714A patent/HU228622B1/hu unknown
- 1998-01-13 CN CNB988019000A patent/CN1271993C/zh not_active Expired - Lifetime
- 1998-01-13 ES ES98901618T patent/ES2235311T5/es not_active Expired - Lifetime
- 1998-01-13 TR TR1999/01690T patent/TR199901690T2/xx unknown
- 1998-01-13 PT PT98901618T patent/PT1007017E/pt unknown
- 1998-01-13 SK SK959-99A patent/SK283950B6/sk not_active IP Right Cessation
- 1998-01-13 ID IDW990663A patent/ID21865A/id unknown
- 1998-01-13 DK DK98901618.3T patent/DK1007017T4/da active
- 1998-01-13 PL PL334527A patent/PL192115B1/pl unknown
- 1998-01-13 IL IL13083898A patent/IL130838A/xx not_active IP Right Cessation
- 1998-01-13 KR KR10-1999-7006414A patent/KR100528416B1/ko active IP Right Grant
- 1998-01-13 EE EEP199900295A patent/EE03951B1/et unknown
- 1998-01-13 RU RU99118587/14A patent/RU2194497C2/ru active
- 1998-01-15 MY MYPI98000164A patent/MY132999A/en unknown
- 1998-01-19 AR ARP980100224A patent/AR011080A1/es not_active Application Discontinuation
- 1998-02-10 SA SA98180818A patent/SA98180818B1/ar unknown
- 1998-03-11 TW TW087103589A patent/TW557217B/zh not_active IP Right Cessation
-
1999
- 1999-07-06 IS IS5108A patent/IS2788B/is unknown
- 1999-07-19 NO NO19993539A patent/NO327426B1/no not_active IP Right Cessation
- 1999-11-02 US US09/431,916 patent/US6287540B1/en not_active Expired - Lifetime
-
2000
- 2000-08-01 HK HK00104814A patent/HK1025515A1/xx not_active IP Right Cessation
-
2009
- 2009-11-06 JP JP2009255070A patent/JP2010059181A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO327426B1 (no) | Torrpulverpreparat, fremgangsmate for fremstilling samt anvendelse av nevnte preparat | |
| US6199607B1 (en) | Formulation for inhalation | |
| KR100528418B1 (ko) | 0.28 내지 0.38 ｇ/㎖의 유동 벌크 밀도를 갖는 부데소니드 함유 신규 흡입 제제 | |
| KR100528417B1 (ko) | 0.28 내지 0.38 ｇ/㎖의 유동 벌크 밀도를 갖는 포르모테롤 함유 신규 흡입 제제 | |
| KR100528415B1 (ko) | 0.28 내지 0.38 ｇ/㎖의 유동 벌크 밀도를 갖는 테르부탈린 술페이트 함유 신규 흡입 제제, 그의 제조 방법 및 그의 용도 | |
| US5980949A (en) | Formulation for inhalation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |